Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma

Liver Transplantation

Volumn 20, Issue 1, 2014, Pages 81-88

  Welling, Theodore H ^a   Feng, Mary ^a   Wan, Shanshan ^a   Hwang, Sin Ye ^a   Volk, Michael L ^a   Lawrence, Theodore S ^a   Zalupski, Mark M ^a   Sonnenday, Christopher J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADJUVANT THERAPY; ADULT; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CHOLANGITIS; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXPLANT; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PILOT STUDY; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR NECROSIS; WHOLE BODY RADIATION; WOUND INFECTION;

AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; DEOXYCYTIDINE; FEMALE; FIBROSIS; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NECROSIS; NEOADJUVANT THERAPY; RADIOSURGERY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896548650     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23757     Document Type: Article

References (17)

1. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz J, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517.
2. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000; 6: 309-316.
3. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006; 82: 1703-1707.
4. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98.e3.
5. Normolle D, Pan C, Ben-Josef E, Lawrence T,. Adaptive trial of personalized radiotherapy for intrahepatic cancer. Per Med 2010; 7: 197-204.
6. Liu E, Stenmark MH, Schipper MJ, Balter JM, Kessler ML, Caoili EM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors. Transl Oncol 2013; 6: 442-446.
7. O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM,. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012; 18: 949-954.
8. Gleeson FC, Rajan E, Levy MJ, Clain JE, Topazian MD, Harewood GC, et al. EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc 2008; 67: 438-443.
9. Gores GJ, Gish RG, Sudan D, Rosen CB,; for MELD Exception Study Group. Model for End-Stage Liver Disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. Liver Transpl 2006; 12 (suppl 3): S95-S97.
10. Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, Ishitani MB, Andrews JC, et al. Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl 2007; 13: 1372-1381.
11. Lau SK, Prakash S, Geller SA, Alsabeh R,. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002; 33: 1175-1181.
12. Rijken AM, Umezawa A, van Gulik TM, Bosma A, Polak MM, Offerhaus GJ, et al. Prognostic value of cell proliferation (Ki-67 antigen) and nuclear DNA content in clinically resectable, distal bile duct carcinoma. Ann Surg Oncol 1998; 5: 699-705.
13. Navarrete MA, Maier CM, Falzoni R, Quadros LG, Lima GR, Baracat EC, Nazário AC,. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res 2005; 7: R306-R313.
14. Singal A, Welling TH, Marrero JA,. Role of liver transplantation in the treatment of cholangiocarcinoma. Expert Rev Anticancer Ther 2009; 9: 491-502.
15. Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ,. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005; 241: 693-699.
16. Rocha FG, Matsuo K, Blumgart LH, Jarnagin WR,. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepatobiliary Pancreat Sci 2010; 17: 490-496.
17. Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 2012; 56: 972-981.